Your browser doesn't support javascript.
loading
The role of N6-methyladenosine RNA modification in platinum resistance.
Wang, Kai; Wang, Lingfang; Chen, Xiaojing; Gu, Jiaxin; Cheng, Xiaodong.
Afiliación
  • Wang K; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  • Wang L; Department of Obstetrics & Gynecology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China.
  • Chen X; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  • Gu J; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  • Cheng X; Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
Epigenomics ; 15(22): 1221-1232, 2023 Nov.
Article en En | MEDLINE | ID: mdl-38009226
Cancer poses a global health challenge, with platinum-based drugs as a cornerstone of treatment. Regrettably, cancer cells can develop resistance to these drugs, diminishing their effectiveness. Recent research suggests that a subtle modification known as N6-methyladenosine (m6A) on RNA molecules may contribute to this resistance. m6A acts as a minuscule tag on RNA molecules within the cells, akin to a genetic switch. When altered, it can render cancer cells less responsive to platinum-based drugs. Scientists have found that m6A changes in various cancer types can bolster resistance to platinum-based drugs. This reduced drug efficacy presents a significant concern, as platinum-based drugs are vital in treating diverse cancer types, including ovarian, lung and colorectal cancer. Understanding the impact of m6A on platinum resistance is pivotal. It may enable doctors to identify patients less likely to respond to treatment. Researchers are also investigating methods to target m6A alterations in cancer cells, potentially rendering them more receptive to platinum-based drugs. Ongoing research into m6A and its role in platinum resistance holds promise for enhancing cancer treatments, ultimately increasing the chances of success for patients requiring platinum-based drugs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenosina / Metilación de ARN Límite: Humans Idioma: En Revista: Epigenomics Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenosina / Metilación de ARN Límite: Humans Idioma: En Revista: Epigenomics Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido